Literature DB >> 26655125

Psychopharmacological treatment of 1650 in-patients with acute mania-data from the AMSP study.

Alexandra Kleimann1, Viktoria Schrader2, Susanne Stübner3, Waldemar Greil4, Kai G Kahl2, Stefan Bleich2, Renate Grohmann5, Helge Frieling2, Sermin Toto2.   

Abstract

BACKGROUND: Several studies have analyzed prescription patterns for bipolar disorder, but few have for acute mania. Treatment strategies in this complex domain change over time and do not always follow evidence-based guidelines.
METHODS: Prescription data of in-patients suffering from acute mania in the time period from 2005 to 2012 were obtained from the database of the Drug Safety Program in Psychiatry (Institut für Arzneimittelsicherheit in der Psychiatrie; AMSP). Data were collected on two index dates per year. Changes over time were analyzed comparing the time periods 2005/06 and 2011/12.
RESULTS: Among 1650 patients (mean ±SD; age: 48.9±14.91 years; 53.1% females) 54.1% received anticonvulsants, 74.5% second-generation antipsychotics (SGAs), 17.8% first-generation antipsychotics (FGAs), 29.1% lithium, 44.1% benzodiazepines and 14.5% antidepressants. Prescription of SGAs increased from 70% to 79% (p=0.005), while prescription of FGAs and anticonvulsants decreased from 19% to 13% (p<0.05) and 59% to 46% (p<0.001), respectively. Only 30% of patients received monotherapy with one mood stabilizer. We observed an impact of gender, age and psychotic symptoms on treatment strategy. 36.8% of the women≤40 years received valproate. LIMITATIONS: Follow-up data are missing and no differentiation between acute and maintenance treatments could be made due to the cross-sectional design. Additionally, our findings do not necessarily translate to outpatients or to other countries.
CONCLUSIONS: Combination therapies represent standard clinical practice. Though many results reflect clinical necessity, the high number of antidepressant prescriptions or valproate use in women of child-bearing age should be judged critically. Further prospective studies should focus on real-world prescription practice in acute mania to evaluate efficacy and safety of common practice. This paper is dedicated to Prof. Dr. Hanns Hippius on the occasion of his 90th birthday.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AMSP; Acute Mania; Antipsychotics; Bipolar Disorder; Gender; Prescription practice

Mesh:

Substances:

Year:  2015        PMID: 26655125     DOI: 10.1016/j.jad.2015.11.037

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  3 in total

Review 1.  Valproate for acute mania.

Authors:  Janina Jochim; Raphael P Rifkin-Zybutz; John Geddes; Andrea Cipriani
Journal:  Cochrane Database Syst Rev       Date:  2019-10-07

2.  Regularity of self-reported daily dosage of mood stabilizers and antipsychotics in patients with bipolar disorder.

Authors:  Maximilian Pilhatsch; Tasha Glenn; Natalie Rasgon; Martin Alda; Kemal Sagduyu; Paul Grof; Rodrigo Munoz; Wendy Marsh; Scott Monteith; Emanuel Severus; Rita Bauer; Philipp Ritter; Peter C Whybrow; Michael Bauer
Journal:  Int J Bipolar Disord       Date:  2018-05-01

Review 3.  Phenothiazines Modified with the Pyridine Ring as Promising Anticancer Agents.

Authors:  Beata Morak-Młodawska; Małgorzata Jeleń; Krystian Pluta
Journal:  Life (Basel)       Date:  2021-03-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.